AAAAAA

   
Results: 1-10 |
Results: 10
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients
Authors: Hensley, ML Hoppe, B Leon, L Sabbatini, P Aghajanian, C Chi, D Spriggs, DR
Citation: Ml. Hensley et al., The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients, GYNECOL ONC, 82(3), 2001, pp. 464-469
Identification of prognostic factors in advanced epithelial ovarian carcinoma
Authors: Chi, DS Liao, JB Leon, LF Venkatraman, ES Hensley, ML Bhaskaran, D Hoskins, WJ
Citation: Ds. Chi et al., Identification of prognostic factors in advanced epithelial ovarian carcinoma, GYNECOL ONC, 82(3), 2001, pp. 532-537
Identification of risk factors for requiring transfusion during front-linechemotherapy for ovarian cancer
Authors: Hensley, ML Lebeau, D Leon, LF Venkatraman, E Waltzman, R Sabbatini, P Almadrones, L Chi, D Spriggs, D
Citation: Ml. Hensley et al., Identification of risk factors for requiring transfusion during front-linechemotherapy for ovarian cancer, GYNECOL ONC, 81(3), 2001, pp. 485-489
Paclitaxel-based chemotherapy in carcinoma of the Fallopian tube
Authors: Gemignani, ML Hensley, ML Cohen, R Venkatraman, E Saigo, PE Barakat, RR
Citation: Ml. Gemignani et al., Paclitaxel-based chemotherapy in carcinoma of the Fallopian tube, GYNECOL ONC, 80(1), 2001, pp. 16-20
Phase I trial of docetaxel (Taxotere) for patients with relapsed or refractory acute myeloid leukemia (AML)
Authors: Szatrowski, TP Hensley, ML Ely, S
Citation: Tp. Szatrowski et al., Phase I trial of docetaxel (Taxotere) for patients with relapsed or refractory acute myeloid leukemia (AML), HEMAT BLOOD, 40, 2001, pp. 477-481
Screening for ovarian cancer: What we know, what we need to know
Authors: Hensley, ML Castiel, M Robson, ME
Citation: Ml. Hensley et al., Screening for ovarian cancer: What we know, what we need to know, ONCOLOGY-NY, 14(11), 2000, pp. 1601-1607
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique - In Reply
Authors: Hensley, ML Schuchter, LM Winer, EP Meropol, NJ Pfister, D
Citation: Ml. Hensley et al., Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique - In Reply, J CL ONCOL, 18(9), 2000, pp. 2005-2006
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of cancer and leukemia Group B 9013
Authors: Hensley, ML Peterson, B Silver, RT Larson, RA Schiffer, CA Szatrowski, TP
Citation: Ml. Hensley et al., Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of cancer and leukemia Group B 9013, J CL ONCOL, 18(6), 2000, pp. 1301-1308
American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants
Authors: Hensley, ML Schuchter, LM Lindley, C Meropol, NJ Cohen, GI Broder, G Gradishar, WJ Green, DM Langdon, RJ Mitchell, B Negrin, R Szatrowski, TP Thigpen, JT Von Hoff, D Wasserman, TH Winer, EP Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Implementation of disease management guidelines in patients with advanced ovarian cancer
Authors: Hensley, ML Sabbatini, P Spriggs, D
Citation: Ml. Hensley et al., Implementation of disease management guidelines in patients with advanced ovarian cancer, SEMIN ONCOL, 26(1), 1999, pp. 46-51
Risultati: 1-10 |